Enlivex (ENLV) Other Non Operating Income (2017 - 2025)
Enlivex (ENLV) posted quarterly Other Non Operating Income of $352000.0 for Q3 2025, down 31.91% year-over-year from $517000.0 in Q3 2024, and down 70.91% quarter-over-quarter from $1.2 million in Q2 2025.
Enlivex (ENLV) Other Non Operating Income (2017 - 2025) Analysis & Trends
Enlivex's Other Non Operating Income history runs 9 years deep, the most recent figure standing at $352000.0 for Q3 2025.
- In Q3 2025, Other Non Operating Income fell 31.91% year-over-year to $352000.0; the TTM figure through Sep 2025 stood at $2.5 million (up 2269.16% YoY), while the FY2024 annual figure was $874000.0, up 171.41% from the prior year.
- Other Non Operating Income for Q3 2025 stood at $352000.0, down from $1.2 million in the prior quarter.
- The five-year high for Other Non Operating Income was $3.1 million in Q4 2021, with the low at -$4.0 million in Q2 2022.
- The 5-year median for Other Non Operating Income is $181500.0 (2024), against an average of $42722.2.
- The sharpest annual moves came in 2022 and 2025: Other Non Operating Income sank 677.43% in 2022, then surged 1200.0% in 2025.
- Enlivex's Other Non Operating Income stood at $3.1 million in 2021, then sank by 78.69% to $656000.0 in 2022, then plunged by 147.41% to -$311000.0 in 2023, then soared by 246.62% to $456000.0 in 2024, then decreased by 22.81% to $352000.0 in 2025.
- Business Quant data shows ENLV's Other Non Operating Income at $352000.0 in Q3 2025, $1.2 million in Q2 2025, and $456000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Enlivex | 4.51 Mn | -1.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 352,000.00 |
| Jun 30, 2025 | 1.21 Mn |
| Dec 31, 2024 | 456,000.00 |
| Sep 30, 2024 | 517,000.00 |
| Jun 30, 2024 | -110,000.00 |
| Mar 31, 2024 | 11,000.00 |
| Dec 31, 2023 | -311,000.00 |
| Sep 30, 2023 | -335,000.00 |
| Jun 30, 2023 | -143,000.00 |
| Mar 31, 2023 | -435,000.00 |
| Dec 31, 2022 | 656,000.00 |
| Sep 30, 2022 | -56,000.00 |
| Jun 30, 2022 | -4.04 Mn |
| Mar 31, 2022 | -1.82 Mn |
| Dec 31, 2021 | 3.08 Mn |
| Sep 30, 2021 | 440,000.00 |
| Jun 30, 2021 | 700,000.00 |
| Mar 31, 2021 | 602,000.00 |
| Dec 31, 2020 | -2.17 Mn |
| Sep 30, 2020 | -166,000.00 |